November 08, 2013
Bernstein Liebhard LLP is investigating whether the Board of Directors of Santarus, Inc. (“Santarus” or the “Company”) (NASDAQ: SNTS) breached its fiduciary duty to its shareholders in agreeing to sell Santarus to Salix Pharmaceuticals, Ltd.
Under the terms of the agreement, Santarus shareholders will receive $32.00 in cash for each share they own. The investigation is focused on the potential unfairness of the price to Santarus shareholders and the process by which the Santarus Board of Directors considered and approved the transaction.
If you are interested in discussing your rights as a Santarus stockholder, with no obligation or cost to you, please contact U. Seth Ottensoser at (877) 779-1414 or Ottensoser@bernlieb.com.
Bernstein Liebhard LLP has pursued hundreds of securities, consumer and shareholder rights cases and recovered over $3 billion for its clients. It has been named to The National Law Journal’s “Plaintiffs’ Hot List” in each of the last eleven years.